High fees jeopardize early access scheme
This article was originally published in Scrip
Executive Summary
The total costs of the UK's newly launched early access to medicines schemes (EAMS), including up to £33,000 in application fees, may be prohibitive for small to medium sized companies, potentially undermining the scheme's proposed purpose of encouraging innovation.